PPT-Treatment of Imatinib -resistant GIST

The Next Generation Dr Michael Heinrich MD OHSU Knight Cancer Institute Portland OR Background Small molecule kinase inhibitors of KITPDGFRA such as imatinib and sunitinib have transformed the medical treatment of advanced GIST. Resistance. Geoffrey L. Uy, M.D.. Associate Professor . of Medicine. Division of Oncology. Natural History of CML. Chronic Phase. Accelerated Phase. Blast Phase. Duration. 3-5 . yrs. , untreated. Varies. Deciding if GIST is right for your ILL office.. T. Jacob (Jake) Weiner – ILL Borrowing Supervisor . George Mason University (VGM). 1. What is the IDS?. The . I. nformation . D. elivery . S. ervices Project (IDS) is a group of libraries in New York state.. . Janghorban. CANB610. 3/8/2012. ETV1 and GIST Pathogenesis. Gastrointestinal . stromal. tumors (GISTs) arise from the interstitial cells of . Cajal. (ICC) in the gastrointestinal tract . Most GISTs have oncogenic mutations in either KIT or platelet-derived growth factor receptor-α (PDGFRA); ~80-85%. Evidence-based Management . of GIST. Program Goals. GIST. Current Treatment Paradigm. What is GIST?. What Causes GIST?. GIST: Treatment. Polling Question #1. Imatinib: Clinical Trial Results. Imatinib: Early Stage GIST. Definition of Gastrointestinal Stromal Tumor . the most common mesenchymal malignancy of (GI) tract. the diagnostic criteria for GIST remained controversial and somewhat confusing. Pathology Terms that Encompass the Spectrum of Gastrointestinal Stromal Tumors. stromal. tumors. Introduction. Tim Butler. March 8. th. , 2012. Topics for Today. GI . Stromal. Tumors (GIST). KIT Signaling. KIT targeted . therapy. ETV1. Interstitial Cells of . Cajal. Discovered by Ramon . . University. of Bologna . Advances. in . cancer. target . pathways. . Roma 8 aprile 2016. Targeting. . molecular. . pathways. . in GIST . La . risposta. ad . imatinib. . dipende. (aka---how to know where to look and who to call). GIST. Rare disease, 5000-7000 new cases of GIST every year . Compare 230,000 new invasive breast CA cases/year. GIST studies tend to be opened at fewer sites . Sarcoma . Medical Oncology. The University of . Miami, Sylvester Cancer Center. Gastrointestinal Stromal . Tumor. Advanced Disease. jtrent@med.miami.edu. Background and Introduction. 4000 to 6000 new GIST are diagnosed in the United States each yr. Associate Professor . of Medicine. Division of Oncology. Natural History of CML. Chronic Phase. Accelerated Phase. Blast Phase. Duration. 3-5 . yrs. , untreated. Varies. Median. of months. Prognosis. Angela . Cioffi. , MD. Sarcoma Research Program coordinator. Mount Sinai Hospital, NY, USA. Istituto. . Europeo. . di. . Oncologia. , IRCSS, Milan, Italy. Today. ’. s job. Review some of the key studies sarcoma that dictate present management. Lillian Klug, PhD . Post-doctoral Scholar, Heinrich Lab. GCRF conference | May 8, 2018. Gastrointestinal stromal tumor (GIST) is a unique disease. GIST is caused by mutations in DNA. Mutations in DNA can turn on the activity of proteins that are normally not active in adults= . I. ntroduction. CML is a clonal myeloproliferative neoplasm. Dysregulated production and uncontrolled proliferation of mature and maturing granulocyte with fairly normal differentiation. Fusion of 2 genes: BCR (or chromosome 22) and ABL1 (on chromosome 9), resulting in BCR-ABL1 fusion gene. Raafat. R. Abdel-. Malek. , MD, FRCR. Ass. Prof Clinical Oncology. Cairo University, Egypt. Introduction. CML is a . myeloproliferative. neoplasm characterized by presence of BCR-ABL fusion gene resulting in uncontrolled proliferation of mature and maturing granulocytes..